Difference between revisions of "Cyclophosphamide (Cytoxan)"
Jump to navigation
Jump to search
m |
m |
||
| Line 43: | Line 43: | ||
*[[Prostate cancer]] | *[[Prostate cancer]] | ||
*[[Rhabdomyosarcoma]] | *[[Rhabdomyosarcoma]] | ||
| − | |||
*[[T-cell acute lymphoblastic leukemia]] | *[[T-cell acute lymphoblastic leukemia]] | ||
*[[Thymoma]] | *[[Thymoma]] | ||
| Line 51: | Line 50: | ||
==Diseases for which it was used== | ==Diseases for which it was used== | ||
| + | *[[Non-small cell lung cancer - historical|Non-small cell lung cancer]] | ||
*[[Ovarian cancer - historical|Ovarian cancer]] | *[[Ovarian cancer - historical|Ovarian cancer]] | ||
*[[Renal cell carcinoma - historical|Renal cell carcinoma]] | *[[Renal cell carcinoma - historical|Renal cell carcinoma]] | ||
| + | *[[Small cell lung cancer - historical|Small cell lung cancer]] | ||
*[[Testicular cancer - historical|Testicular cancer]] | *[[Testicular cancer - historical|Testicular cancer]] | ||
| Line 180: | Line 181: | ||
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
[[Category:Rhabdomyosarcoma medications]] | [[Category:Rhabdomyosarcoma medications]] | ||
| − | |||
[[Category:T-cell acute lymphoblastic leukemia medications]] | [[Category:T-cell acute lymphoblastic leukemia medications]] | ||
[[Category:Thymoma medications]] | [[Category:Thymoma medications]] | ||
| Line 186: | Line 186: | ||
[[Category:Waldenström macroglobulinemia medications]] | [[Category:Waldenström macroglobulinemia medications]] | ||
| + | [[Category:Non-small cell lung cancer medications (historic)]] | ||
[[Category:Ovarian cancer medications (historic)]] | [[Category:Ovarian cancer medications (historic)]] | ||
[[Category:Renal cell carcinoma medications (historic)]] | [[Category:Renal cell carcinoma medications (historic)]] | ||
| + | [[Category:Small cell lung cancer medications (historic)]] | ||
[[Category:Testicular cancer medications (historic)]] | [[Category:Testicular cancer medications (historic)]] | ||
Revision as of 13:45, 26 April 2022
General information
Class/mechanism: Alkylating agent; transformed primarily in the liver to active metabolites which alkylate and crosslink DNA.[1][2]
Route: IV, PO
Extravasation: irritant or neutral, depending on reference; n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acquired coagulopathy
- Acute myeloid leukemia
- Adult T-cell leukemia-lymphoma
- Anaplastic glioma
- Anaplastic large cell lymphoma
- B-cell acute lymphoblastic leukemia
- Bladder cancer
- Breast cancer
- Burkitt lymphoma
- Central nervous system (CNS) cancer
- Chronic lymphocytic leukemia
- Chronic myelogenous leukemia
- CNS lymphoma
- Diffuse large B-cell lymphoma
- Ewing sarcoma
- Follicular lymphoma
- Glioblastoma
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Large granular lymphocytic leukemia
- Light-chain (AL) amyloidosis
- Mantle cell lymphoma
- Marginal zone lymphoma
- Mediastinal gray-zone lymphoma
- Medulloblastoma
- Multiple myeloma
- Osteosarcoma
- Peripheral T-cell lymphoma
- Pheochromocytoma
- Plasma cell leukemia
- Post-transplant lymphoproliferative disorder
- Primary mediastinal B-cell lymphoma
- Prostate cancer
- Rhabdomyosarcoma
- T-cell acute lymphoblastic leukemia
- Thymoma
- Transformed lymphoma
- Waldenström macroglobulinemia
Diseases for which it was used
- Non-small cell lung cancer
- Ovarian cancer
- Renal cell carcinoma
- Small cell lung cancer
- Testicular cancer
Patient drug information
- Cyclophosphamide (Cytoxan) package insert[1]
- Cyclophosphamide (Cytoxan) patient drug information (Chemocare)[3]
- Cyclophosphamide (Cytoxan) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 11/16/1959: initial FDA approval
- 3/31/2012: (earliest label available at Drugs@FDA) Approved for malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt lymphoma; multiple myeloma, leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration); mycosis fungoides (advanced disease); neuroblastoma (disseminated disease); adenocarcinoma of ovary; retinoblastoma; carcinoma of the breast
Also known as
- Code names: Asta B 518, B-518, WR-138719
- Generic names: CP monohydrate, CPM, cyclophosphamid monohydrate, cyclophosphamide monohydrate
- Brand names:
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Alkyloxan | Biodoxan | Carloxan | Ciclofosfamida | Ciclokebir | Cicloxal | Clafen | Claphene |
| Cyclam | Cycloblastin | Cycloblastine | CYCLO-cell | Cycloferon | Cyclomide | Cyclophar | Cyclophospham |
| Cyclophosphamid | Cyclophosphane | Cyclostin | Cyclostine | Cyclotox | Cycloxan | Cycram | Cydoxan |
| Cyklofosfamid | Cyphos | Cytophosphan | Cytoxan | Cytoxan Lyophilized | Endoxan | Endoxan-N | Endoxana |
| Enduxan | Formitex | Fosfaseron | Genoxal | Genuxal | Hidrofosmin | Ledoxan | Ledoxina |
| Mitoxan | Neophos | Neosar | Oncomide | Oncophos | Procytox | Revimmune | Sendoxan |
| Siklofos | Syklofosfamid | Tymtran | Zuviphos | Zycram | Zytoxan | ||
References
Categories:
- Drugs
- Intravenous medications
- Oral medications
- Irritant
- Neutral
- Alkylating agents
- Nitrogen mustards
- Immunosuppressants
- Acquired coagulopathy medications
- Acute myeloid leukemia medications
- Adult T-cell leukemia-lymphoma medications
- Anaplastic glioma medications
- Anaplastic large cell lymphoma medications
- B-cell acute lymphoblastic leukemia medications
- Bladder cancer medications
- Breast cancer medications
- Burkitt lymphoma medications
- CNS lymphoma medications
- Chronic lymphocytic leukemia medications
- Chronic myelogenous leukemia medications
- Diffuse large B-cell lymphoma medications
- Ewing sarcoma medications
- Follicular lymphoma medications
- Glioblastoma medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Large granular lymphocytic leukemia medications
- Light-chain (AL) amyloidosis medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Mediastinal gray-zone lymphoma medications
- Medulloblastoma medications
- Multiple myeloma medications
- Osteosarcoma medications
- Peripheral T-cell lymphoma medications
- Pheochromocytoma medications
- Plasma cell leukemia medications
- Post-transplant lymphoproliferative disorder medications
- Primary mediastinal B-cell lymphoma medications
- Prostate cancer medications
- Rhabdomyosarcoma medications
- T-cell acute lymphoblastic leukemia medications
- Thymoma medications
- Transformed lymphoma medications
- Waldenström macroglobulinemia medications
- Non-small cell lung cancer medications (historic)
- Ovarian cancer medications (historic)
- Renal cell carcinoma medications (historic)
- Small cell lung cancer medications (historic)
- Testicular cancer medications (historic)
- FDA approved in 1959
- PMDA approved drugs
- WHO Essential Cancer Medicine